Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $56.9091.

A number of research firms have weighed in on JANX. Stifel Nicolaus cut their price target on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Piper Sandler dropped their price objective on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 16th. Bank of America cut their target price on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Finally, Cantor Fitzgerald lowered their price target on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research report on Friday, February 27th.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $25,798.67. Following the transaction, the insider directly owned 83,095 shares of the company’s stock, valued at $1,140,894.35. The trade was a 2.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO David Alan Campbell sold 8,072 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the sale, the chief executive officer owned 284,982 shares of the company’s stock, valued at $3,912,802.86. The trade was a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 19,033 shares of company stock worth $261,323. 29.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System increased its position in shares of Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after acquiring an additional 404 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Janux Therapeutics by 8.1% during the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after acquiring an additional 771 shares in the last quarter. Nuveen LLC boosted its position in Janux Therapeutics by 0.8% during the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after purchasing an additional 787 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares in the last quarter. Finally, Virtus Investment Advisers LLC increased its holdings in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after purchasing an additional 1,011 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $14.06 on Monday. The firm’s 50-day simple moving average is $13.71 and its 200-day simple moving average is $19.63. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The firm has a market cap of $855.27 million, a P/E ratio of -7.68 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.14. The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $0.08 million. Analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.